Use of liposomal doxorubicin for adjuvant chemotherapy of breast cancer in clinical practice-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Use of liposomal doxorubicin for adjuvant chemotherapy of breast cancer in clinical practice

Published:2017-01 Issue:1 Volume:18 Page:15-26
ISSN:1673-1581
Container-title:Journal of Zhejiang University-SCIENCE B
language:en
Short-container-title:J. Zhejiang Univ. Sci. B

Author:

Zhao Ming,Ding Xian-feng,Shen Jian-yu,Zhang Xi-ping,Ding Xiao-wen,Xu Bin

Funder

“151” Excellent Middle-Aged and Talented Young Persons of Zhejiang Province, China

Key Platform Technological Project of Zhejiang Medical Science and Hygiene, China

Publisher

Zhejiang University Press

Subject

General Pharmacology, Toxicology and Pharmaceutics,General Veterinary,General Biochemistry, Genetics and Molecular Biology,General Medicine

Link

http://link.springer.com/content/pdf/10.1631/jzus.B1600303.pdf

Reference56 articles.

1. Abdel-Fatah, T.M., Perry, C., Dickinson, P., et al., 2013. Bcl2 is an independent prognostic marker of triple negative breast cancer (TNBC) and predicts response to anthracycline combination (ATC) chemotherapy (CT) in adjuvant and neoadjuvant settings. Ann. Oncol., 24(11):2801–2807. http://dx.doi.org/10.1093/annonc/mdt277

2. Addeo, R., Faiola, V., Guarrasi, R., et al., 2008. Liposomal pegylated doxorubicin plus vinorelbine combination as first-line chemotherapy for metastatic breast cancer in elderly women > or =65 years of age. Cancer Chemother. Pharmacol., 62(2):285–292. http://dx.doi.org/10.1007/s00280-007-0605-6

3. Airoldi, M., Amadori, D., Barni, S., et al., 2011. Clinical activity and cardiac tolerability of non-pegylated liposomal doxorubicin in breast cancer: a synthetic review. Tumori, 97(6):690–692.

4. Anders, C.K., Adamo, B., Karginova, O., et al., 2013. Pharmacokinetics and efficacy of PEGylated liposomal doxorubicin in an intracranial model of breast cancer. PLoS ONE, 8(5):e61359. http://dx.doi.org/10.1371/journal.pone.0061359

5. Antón, A., Ruiz, A., Plazaola, A., et al., 2011. Phase II clinical trial of liposomal-encapsulated doxorubicin citrate and docetaxel, associated with trastuzumab, as neoadjuvant treatment in stages II and IIIA HER-2-overexpressing breast cancer patients. GEICAM 2003-03 study. Ann. Oncol., 22(1):74–79. http://dx.doi.org/10.1093/annonc/mdq317

Cited by 57 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Lipid-Based Nanocarriers: Bridging Diagnosis and Cancer Therapy;Pharmaceutics;2024-09-01

2. Unbiased discovery of cancer pathways and therapeutics using Pathway Ensemble Tool and Benchmark;Nature Communications;2024-08-24

3. Tarin-Loaded Nanoliposomes Activate Apoptosis and Autophagy and Inhibit the Migration of Human Mammary Adenocarcinoma Cells;International Journal of Nanomedicine;2023-11

4. Current perspectives and trends in nanoparticle drug delivery systems in breast cancer: bibliometric analysis and review;Frontiers in Bioengineering and Biotechnology;2023-09-12

5. Label-free identification of cell death mechanism using scattering-based microscopy and deep learning;Journal of Physics D: Applied Physics;2023-09-04

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3